View Older Stories View More Recent Stories

May 13, 2024 05:33AM ERS Genomics Appoints John E Milad as Chief Executive Officer
May 10, 2024 12:00PM Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
May 9, 2024 07:30AM Nvelop Therapeutics to Share the First Preclinical Data from its Novel, Humanized Particle Platform for In Vivo Delivery of Genetic Cargoes at the ASGCT Annual Meeting
May 6, 2024 06:16AM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 2, 2024 08:30AM Nvelop Therapeutics Announces Members of Its Scientific Advisory Board
May 2, 2024 07:08AM Mariana Oncology to be Acquired by Novartis (NVS) to Advance Precision Radiopharmaceuticals to Treat Cancer
May 2, 2024 07:00AM Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
Apr 25, 2024 07:00AM Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
Apr 23, 2024 05:24PM Form 4 Korro Bio, Inc. For: Apr 22 Filed by: Atlas Venture Associates Opportunity II, LP
Apr 23, 2024 09:00AM Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Apr 18, 2024 08:32AM Korro Bio (KRRO) Announces $70M Placement
Apr 18, 2024 08:30AM Korro Announces $70 Million Private Placement
Apr 9, 2024 06:43PM Form 144 Aerovate Therapeutics, Filed by: Atlas Venture Associates XII, L.P.
Apr 9, 2024 07:00AM Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines
Apr 3, 2024 08:00AM Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
Apr 3, 2024 06:00AM Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseas
Apr 2, 2024 08:05AM MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Apr 1, 2024 09:53PM Form SC 13D Q32 Bio Inc. Filed by: Atlas Venture Fund X, L.P.
Mar 28, 2024 03:00AM Inventiva announces the nomination of Andre Turenne as Director
Mar 27, 2024 05:17PM Form 3 Q32 Bio Inc. For: Mar 25 Filed by: Atlas Venture Opportunity Fund II, L.P.
Mar 25, 2024 04:15PM Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Mar 15, 2024 04:34PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 15, 2024 04:33PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Mar 14, 2024 05:03PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 14, 2024 05:02PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Mar 13, 2024 07:54PM Form 4 Kymera Therapeutics, For: Mar 11 Filed by: Atlas Venture Associates Opportunity I, L.P.
Mar 13, 2024 04:56PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 13, 2024 04:56PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Mar 13, 2024 07:00AM Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
Mar 12, 2024 05:18PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Mar 12, 2024 05:03PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 11, 2024 05:05PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Mar 11, 2024 05:02PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 6, 2024 07:00AM Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis
Mar 5, 2024 06:47PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 5, 2024 06:46PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Mar 5, 2024 05:07PM Form 4 Dyne Therapeutics, Inc. For: Mar 01 Filed by: Atlas Venture Opportunity Fund II, L.P.
Mar 1, 2024 05:11PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Mar 1, 2024 05:08PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
Feb 28, 2024 07:14PM Form 4 Dyne Therapeutics, Inc. For: Feb 26 Filed by: Atlas Venture Opportunity Fund II, L.P.
Feb 28, 2024 04:38PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 27, 2024 05:24PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 26, 2024 04:43PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 23, 2024 06:59PM Form 4 Dyne Therapeutics, Inc. For: Feb 21 Filed by: Atlas Venture Opportunity Fund II, L.P.
Feb 23, 2024 05:29PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
Feb 23, 2024 05:20PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 23, 2024 05:19PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 23, 2024 05:16PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 20, 2024 06:36PM Form 4 Dyne Therapeutics, Inc. For: Feb 15 Filed by: Atlas Venture Associates XI, LLC
Feb 20, 2024 05:14PM Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
View More Recent Stories View Older Stories